[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643856":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":38,"locations":44,"responsibleParty":89,"collaborators":29,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":29,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":29,"enrollmentInfo":102,"targetDuration":29,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":122,"whyStopped":29,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Norepinephrine group","EXPERIMENTAL","The initial dose is 0.02 mg\u002Fkg\u002Fmin of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg\u002Fkg\u002Fmin of norepinephrine; the maximum dose of norepinephrine is 0.2 mg\u002Fkg\u002Fmin.",[13],"Drug: Norepinephrine",{"label":15,"type":10,"description":16,"interventionNames":17},"Dopamine group","The initial dose is 2 μg\u002Fkg\u002Fmin of dopamine; each dose adjustment (increase or decrease) is 2 μg\u002Fkg\u002Fmin of dopamine; the maximum dose of dopamine is 20 μg\u002Fkg\u002Fmin.",[18],"Drug: Dopamine",{"label":20,"type":10,"description":21,"interventionNames":22},"Epinephrine group","The initial dose is 0.02 μg\u002Fkg\u002Fmin of epinephrine; each adjustment (increase or decrease) is 0.02 μg\u002Fkg\u002Fmin of epinephrine; the maximum dose of epinephrine is 0.2 μg\u002Fkg\u002Fmin",[23],"Drug: Epinephrine",[25,30,34],{"type":26,"name":27,"description":11,"armGroupLabels":28,"otherNames":29},"DRUG","Norepinephrine",[9],null,{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Dopamine","The initial dose is 2 μg\u002Fkg\u002Fmin of dopamine; each dose adjustment (increase or decrease) is 2 μg\u002Fkg\u002Fmin of dopamine; the maximum dose of dopamine is 20 μg\u002Fkg\u002Fmin",[15],{"type":26,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Epinephrine","The initial dose is 0.02 μg\u002Fkg\u002Fmin of epinephrine; each adjustment (up or down) is 0.02 μg\u002Fkg\u002Fmin of epinephrine; the maximum dose of epinephrine is 0.2 μg\u002Fkg\u002Fmin",[20],[39],{"name":40,"role":41,"phone":42,"phoneExt":29,"email":43},"Qing Gu,MD","CONTACT","+86 010-88392814","guqingfw@126.com",[45,60,75],{"facility":46,"status":29,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Chinese Academy of Medical Sciences, Fuwai Hospital","Beijing","Beijing Municipality","10037","China","CN",{"type":53,"coordinates":54},"Point",[55,56],116.39723,39.9075,{"lat":56,"lon":55},[59],{"name":40,"role":41,"phone":42,"phoneExt":29,"email":43},{"facility":61,"status":29,"city":62,"state":63,"zip":64,"country":50,"countryCode":51,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Guangdong Provincial People's Hospital","Guangzhou","Guangdong","510180",{"type":53,"coordinates":66},[67,68],113.25,23.11667,{"lat":68,"lon":67},[71],{"name":72,"role":41,"phone":73,"phoneExt":29,"email":74},"Li Huang","+86 020-83827812","huangli1991ly@126.com",{"facility":76,"status":29,"city":77,"state":77,"zip":78,"country":50,"countryCode":51,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Zhongnan Hospital of Wuhan University","Wuhan","430072",{"type":53,"coordinates":80},[81,82],114.26667,30.58333,{"lat":82,"lon":81},[85],{"name":86,"role":41,"phone":87,"phoneExt":29,"email":88},"Gangcheng Zhang","+86 027-68756878","zgcsir@163.com",{"type":90,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":46,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Qing Gu","Study Chair","100643856","vasopressor-agents-in-pulmonary-hypertension-crisis-100643856",false,"NCT07667829","Vasopressor Agents in Pulmonary Hypertension Crisis","Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring","Inclusion Criteria:\n\n1. Age \\> 18 years old;\n2. Signed informed consent form;\n3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and\u002For chronic thromboembolic pulmonary hypertension (CTEPH);\n4. Presenting with manifestations of pulmonary hypertensive crisis;\n5. Receiving both diagnosis and treatment in-hospital;\n6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.\n\nExclusion Criteria:\n\n1. At SCAI stage D or stage E ;\n2. Patients who only receive a diagnosis but no treatment in the hospital;\n3. Uncontrolled hyperthyroidism;\n4. Complicated with angle-closure glaucoma;\n5. Hypersensitivity to the study drug;\n6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;\n7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);\n8. Pregnancy;\n9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.","ALL","18 Years",{"count":103,"type":104},75,"ESTIMATED","INTERVENTIONAL",[107],"NA","Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring",[110,111,112],"Pulmonary Arterial Hypertension (PAH)","Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","Hypertension, Pulmonary",[112,114,115,31,27,35,116,117,118,119,120,121],"Cardiovascular Diseases","Vascular Diseases","Haemodynamic Monitoring","Efficacy and Safety","Chronic thromboembolic pulmonary hypertension","Heart Failure","Pulmonary circulation","Pulmonary Arterial Hypertension","NOT_YET_RECRUITING","2026-06-21",{"date":125,"type":126},"2026-06-25","ACTUAL",{"date":128,"type":104},"2026-06",{"date":130,"type":104},"2029-01-31",{"name":5,"class":6},3]